Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis

Molecular Cancer Therapeutics

Volumn 5, Issue 3, 2006, Pages 522-532

  Sanderson, Sharon ^a   Valenti, Melanie ^a   Gowan, Sharon ^a   Patterson, Lisa ^a   Ahmad, Zahida ^a   Workman, Paul ^a   Eccles, Suzanne A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 (DIMETHYLAMINOETHYLAMINO) 17 DEMETHOXYGELDANAMYCIN; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; BENZOQUINONE DERIVATIVE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; MATRIGEL; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CAVA VEIN; CELL DIFFERENTIATION; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENSITY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MESENTERY BLOOD VESSEL; METASTASIS; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; CAPILLARIES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTAXIS; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; FOCAL ADHESION KINASE 1; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; QUINONES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RIFABUTIN; UMBILICAL CORD; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645470397     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0439     Document Type: Article

References (50)

1. Bicknell R, Harris AL. Novel angiogenic signaling pathways and vascular targets. Annu Rev Pharmacol Toxicol 2004;44:219-38.
2. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23: 1011-27.
3. Loureiro RM, D'Amore PA. Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine Growth Factor Rev 2005; 16:77-89.
4. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005;94:209-31.
5. He Y, Karpanen T, Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta 2004;1654:3-12.
6. Zachary I. VEGF signaling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003;31:1171-7.
7. Brader S, Eccles SA. Phosphoinositide 3-kinase signaling pathways in tumor progression, invasion and angiogenesis. Tumori 2004;90:2-8.
8. Rakic JM, Maillard C, Jost M, et al. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci 2003;60:463-73.
9. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005;9:267-85.
10. Bingle L, Brown NJ, Lewis CE. The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol 2002;196:254-65.
11. Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of Hsp90 inhibitors. Curr Cancer Drug Targets 2003;3:349-58.
12. Sreedhar AS, Kalmar E, Csermely P, Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 2004;562: 11-5.
13. Argon Y, Simen BB. Grp94, an ER chaperone with protein and peptide binding properties. Semin Cell Dev Biol 1999;10:495-505.
14. Felts SJ, Owen BAL, Nguyen P, Trepel J, Donner DB, Toft DO. The Hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 2000;5:3305-12.
15. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004;3:1021-30.
16. Banerji U, Judson I, Workman P. The clinical applications of heat shock protein inhibitors in cancer-present and future. Curr Cancer Drug Targets 2003;3:385-90.
17. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7.
18. Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin Emerg Drugs 2005; 10:137-49.
19. Workman P. Combinatorial attack on multistep carcinogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004;206: 149-57.
20. Trochron T, Li H, Frankeene F, et al. Endothelial metalloprotease-disintegrin protein (ADAM) is implicated in angiogenesis in vitro. Angiogenesis 1998;2:277-85.
21. Lawley TJ, Kubota Y. Induction of morphologic differentiation of endothelial cells in culture. J Invest Dermatol 1989;93:59-61S.
22. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Coordinating Committee on Cancer Research guidelines for the welfare of animals in experimental neoplasia. 2nd ed. Br J Cancer 1998;77:1-10.
23. Patel S, Turner PR, Stubberfield C, et al. Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer. Int J Cancer 2002;97:416-24.
24. Kim HS, Shin HS, Kwak HJ, Cho CH, Lee CO, Koh GY. Betacellulin induces angiogenesis through activation of mitogen-activated protein kinase and phosphatidylinositol 3′-kinase in endothelial cell. FASEB J 2003;17:318-20.
25. O-charoenrat P, Rhys-Evans P, Modjtahedi H, Eccles SA. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 2000;18:155-61.
26. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-30.
27. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J Biol Chem 2002;277:29936-44.
28. Kaur G, Belotti D, Burger AM, et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004;10: 4813-21.
29. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature 2003;425: 407-10.
30. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
31. Bagatell R, Paine-Murrieta GD, Taylor CW, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000;6:3312-8.
32. Webb CP, Hose CD, Koochekpour S, et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-Met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000;60:342-9.
33. Xie Q, Gao CF, Shinomiya N, et al. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 2005;24: 3697-707.
34. Hsia DA, Mitra SK, Hauck CR, et al. Differential regulation of cell motility and invasion by FAK. J Cell Biol 2003;160:753-67.
35. Schaller MD. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 2001;1540:1-21.
36. Ochel H-J, Schulte TW, Nguyen P, Trepel J, Neckers L. The benzoquinone ansamycin geldanamycin stimulates the proteolytic degradation of focal adhesion kinase. Mol Genet Metab 1999;66:24-30.
37. 3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones 2003;8:37-52.
38. Morales-Ruiz M, Fulton D, Sowa G, et al. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ Res 2000; 86:892-6.
39. Webb DJ, Parsons JT, Horwitz AF. Adhesion assembly, disassembly and turnover in migrating cells - over and over and over again. Nat Cell Biol 2002;4:E97-100.
40. Foda HD, Zucker S. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today 2001;6:478-82.
41. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001;33:960-70.
42. Bussolino F, Di Renzo M, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-41.
43. Xu W, Mimnaugh E, Rosser MF, et al. Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 2001;276:3702-8.
44. Le Boeuf F, Houle F, Huot J. Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem 2004;279: 39175-85.
45. Isaacs JS. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up? Expert Opin Investig Drugs 2005;14:569-89.
46. Banerji U, Walton M, Raynaud F, et al. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005;11:7023-32.
47. Burger AM, Fiebig HH, Stinson SF, Sausville EA. 17-(Allylamino)-17 demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 2004;15:377-87.
48. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23: 4152-61.
49. de Candia P, Solit DB, Giri D, et al. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci U S A 2003;100: 12337-42.
50. Eccles SA. Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention. Int J Dev Biol 2004;48:583-98.